{"id":8863,"date":"2026-03-25T13:33:14","date_gmt":"2026-03-25T13:33:14","guid":{"rendered":"https:\/\/drhasanmorcali.com\/immunoterapi-nedir-kanser-tedavisinde-nasil-uygulanir"},"modified":"2026-06-10T06:50:20","modified_gmt":"2026-06-10T06:50:20","slug":"what-is-immunotherapy-how-is-it-applied-in-cancer-treatment","status":"publish","type":"post","link":"https:\/\/drhasanmorcali.com\/en\/what-is-immunotherapy-how-is-it-applied-in-cancer-treatment","title":{"rendered":"What Is Immunotherapy? How Is It Applied in Cancer Treatment?"},"content":{"rendered":"

One of the topics most wondered about by patients diagnosed with cancer and their relatives is understanding how the available treatment options work and under which conditions they come into consideration. In the middle of these questions there is a concept that has increasingly begun to be talked about in recent years: immunotherapy.<\/p>\n

What Is Immunotherapy, What Distinguishes It From Conventional Chemotherapy?<\/h2>\n

Immunotherapy is the general name for the treatment approaches that aim to direct the body’s immune system more effectively against cancer cells. Instead of directly targeting cancer cells like conventional chemotherapy, it works through mechanisms aimed at supporting the immune system’s capacity to recognise these cells and respond to them.<\/p>\n

In conventional chemotherapy, rapidly dividing cells are targeted; for this reason, besides tumour cells, healthy tissues such as the hair root, the digestive system mucosa and the bone marrow can also be affected. Cancer immunotherapy<\/a>, on the other hand, follows a different path: it aims to prevent the suppression of immune cells in the tumour microenvironment or to support the directing of these cells towards the tumour.<\/p>\n

An important nuance is this: immunotherapy is not a single drug that replaces conventional chemotherapy. It is gathered under various approaches that can be evaluated for different mechanisms and different patient profiles. Saying that the same thing applies to everyone who hears the heading “immunotherapy” is not correct.<\/p>\n

How Does the Immune System Recognise Cancer Cells?<\/h2>\n

One of the basic functions of the immune system is to recognise the abnormal structures in the body and to form a response to them. Immune components such as the T cell and the NK (natural killer) cell carry out this recognition work through the markers on the cell surface.<\/p>\n

Cancer cells, in turn, can over time develop mechanisms that make this recognition process difficult. Some tumours create signalling pathways that prevent the activity of immune cells. Checkpoint proteins such as PD-L1 are among the most studied of these suppressive mechanisms. Checkpoint inhibitors, a branch of immunotherapy, come into play exactly at this point and aim to support the reactivation of immune cells against the tumour.<\/p>\n

However, how effectively this recognition process works can vary from patient to patient. For this reason, in the treatment decision, the biological profile of the tumour and some biomarkers related to the immune system are evaluated together.<\/p>\n

What Are the Types of Immunotherapy?<\/h2>\n

“Immunotherapy” describes not a single drug, but a group of approaches that work through mechanisms different from one another. Although these groups are generally explained to patients as if they were interchangeable options, the path by which each works and the patient profile each is suitable for are different.<\/p>\n

Checkpoint Inhibitors<\/h3>\n

These constitute the immunotherapy class with the broadest clinical experience today. These drugs, aimed at targets such as PD-1, PD-L1 and CTLA-4, aim to prevent the suppression of immune cells by the tumour. They have been studied within the scope of clinical trials in various cancer types such as melanoma, non-small cell lung cancer and bladder cancer.<\/p>\n

CAR-T Cell Treatment<\/h3>\n

This is an approach that enables the patient’s own T cells to be genetically reprogrammed in a laboratory environment to recognise tumour-specific targets. Although it has been taken within the scope of clinical assessment in some haematological cancer types, its application in solid tumours continues to be at the research stage.<\/p>\n

Therapeutic Cancer Vaccine<\/h3>\n

Unlike preventive vaccines, these are treatment-oriented approaches that aim to stimulate the immune system against certain tumour antigens after a cancer diagnosis. They are not applied routinely for every cancer type and every patient; they are addressed within the framework of clinical assessment.<\/p>\n

Monoclonal Antibodies<\/h3>\n

These are drug classes that target certain tumour surface markers and act through the immune system. While some aim to directly affect cell signalling, some aim to direct immune cells towards the tumour. Some drugs referred to as “smart chemotherapy” technically fall within this group.<\/p>\n

In Which Cancer Types Can It Come Into Consideration?<\/h2>\n

Cancer immunotherapy was initially researched in a limited number of cancer types; however, the scope of clinical trials has expanded over time. Today, the immunotherapy approach is being taken within the scope of clinical assessment in various types such as melanoma, non-small cell lung cancer, bladder cancer, renal cell carcinoma and Hodgkin lymphoma.<\/p>\n

In which cancer type and at which stage immunotherapy can come into consideration varies on a patient basis. Biomarkers such as the molecular profile of the tumour, the PD-L1 expression level and the tumour mutational burden (TMB) are among the factors taken into account in this assessment. That is, the test result can affect the options, but it does not determine the treatment decision on its own.<\/p>\n

Like all oncological treatments<\/a>, immunotherapy is also not a standard application for every patient. The assessment regarding the treatment options is carried out in line with the clinical findings and current guidelines.<\/p>\n

How Is Immunotherapy Applied, How Does the Process Work?<\/h2>\n

The great majority of immunotherapy drugs are applied by the intravenous infusion method. These infusions can be carried out at certain intervals in outpatient treatment conditions. The frequency and duration of the application vary according to the drug used and the treatment protocol.<\/p>\n

Some forms of immunotherapy, in turn, can be used orally in the form of a tablet or capsule. These options are evaluated in patient groups deemed suitable and are addressed as part of the clinical assessment process.<\/p>\n

Before the application begins, the patient’s general condition, organ functions, accompanying diseases and previous treatments are evaluated in detail. Regular blood monitoring and clinical follow-up are planned during the treatment process. Any kind of symptom that may arise should be shared with the treatment team.<\/p>\n

Are the Side Effects Fewer, or Can They Follow a Different Course?<\/h2>\n

A frequently heard sentence for immunotherapy is “the side effects are much fewer”. This generalisation can sometimes be correct; however, the more accurate expression is often “the side-effect profile differs”. While situations such as hair loss or bone marrow suppression, which are seen more frequently in conventional chemotherapy, may decrease, different effects associated with the activation of the immune system may arise.<\/p>\n

Fatigue, skin changes, shortness of breath, joint pain or symptoms related to the digestive system may be early indicators of immune system-related side effects. These symptoms may be manageable when noticed early. For this reason, relying on a generalisation such as “immunotherapy does not cause side effects” is not correct; regular monitoring and early reporting hold a critical place in terms of your process proceeding safely.<\/p>\n

For Whom Can It Be Considered, How Is the Treatment Decision Shaped?<\/h2>\n

Although it is possible to give general preliminary information about in which patients immunotherapy is evaluated, the suitability for each patient is addressed separately in the clinical assessment process. The type and stage of the tumour, the biomarker profile, previous treatments and the patient’s general health condition are among the factors taken into account together in this assessment.<\/p>\n

While for some patients immunotherapy can come into consideration as a first-line treatment option, for some it can be addressed after standard treatments or in combination with these treatments. Situations such as a history of autoimmune disease, an active infection or certain organ function disorders can be counted among the factors that can affect the suitability assessment. For all these reasons, a detailed medical assessment is an indispensable step in determining the correct treatment option.<\/p>\n

What Should Be Paid Attention to During the Immunotherapy Process?<\/h2>\n

Patients receiving immunotherapy should be proactive about sharing the symptoms and changes that may arise during the treatment process with the treatment team. Fatigue, skin changes, shortness of breath, joint pain or symptoms related to the digestive system may be early indicators of immune system-related side effects and can be managed more easily when reported early.<\/p>\n

Regular blood tests and imaging assessments are planned during the treatment process. These follow-up appointments undertake a critical role in terms of evaluating the response given to treatment and noticing possible side effects at an early stage. Informing the treatment team in advance about vaccines and the use of some drugs is also recommended; such interactions can from time to time affect the treatment process.<\/p>\n

Frequently Asked Questions<\/h2>\n

Does immunotherapy replace conventional chemotherapy?<\/h4>\n

Not always. While it can be evaluated on its own in some situations, it can be planned together with chemotherapy or other treatments in some situations. This decision is shaped according to the characteristics of the tumour and the patient’s clinical picture.<\/p>\n

Is a biomarker test necessary for everyone?<\/h4>\n

Which biomarker test will be meaningful is determined according to the cancer type, the stage and the clinical question. The same tests are not applied in every patient. Which tests are necessary in treatment planning is evaluated by your oncology team.<\/p>\n

If the biomarker test is positive, will treatment definitely provide benefit?<\/h4>\n

The detection of a target or a biomarker makes it easier to evaluate some options, but it does not mean a definite result on its own. The test result is interpreted together with the clinical picture and other findings. A negative result also does not mean that all doors are closed; different approaches can come into consideration.<\/p>\n

Are immunotherapy and smart chemotherapy the same thing?<\/h4>\n

No, they are different treatment classes. The targeted treatments referred to as smart chemotherapy directly target a certain molecular structure on the tumour cell. Immunotherapy, on the other hand, works through mechanisms that regulate the immune system’s interaction with cancer. In some situations, these two approaches can be planned together or sequentially.<\/p>\n

Can it be understood at the first examination whether immunotherapy is suitable?<\/h4>\n

A single examination is generally not sufficient. The pathology results, biomarker tests, imaging findings and the patient’s general health condition need to be evaluated together. This process is a critical precondition for determining the correct treatment option.<\/p>\n

This text is for general information purposes and does not replace a medical assessment. How immunotherapy is evaluated in your situation is planned by the physician team together with the tumour type, stage, pathology and biomarker results.<\/p>\n","protected":false},"excerpt":{"rendered":"

One of the topics most wondered about by patients diagnosed with cancer and their relatives is understanding how the available treatment options work and under which conditions they come into consideration. In the middle of these questions there is a concept that has increasingly begun to be talked about in recent years: immunotherapy. What Is […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[],"class_list":["post-8863","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/posts\/8863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/comments?post=8863"}],"version-history":[{"count":4,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/posts\/8863\/revisions"}],"predecessor-version":[{"id":8870,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/posts\/8863\/revisions\/8870"}],"wp:attachment":[{"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/media?parent=8863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/categories?post=8863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drhasanmorcali.com\/en\/wp-json\/wp\/v2\/tags?post=8863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}